This trial is evaluating whether Unified Protocol will improve 6 primary outcomes and 2 secondary outcomes in patients with Depression. Measurement will happen over the course of through study completion, an average of 12 weeks.
This trial requires 26 total participants across 2 different treatment groups
This trial involves 2 different treatments. Unified Protocol is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Depression may be caused by or be caused by other conditions. It may also be due to a combination of multiple causes. It is not known what specific conditions will cause depression, so it has to be treated as a condition in itself. Most cases of depression are treatable but the treatment may also lead to other problems including depression in people's families.
Depression can be diagnosed and may lead to suicide. The main signs and symptoms of depression are, fatigue, depression and lethargy. Depression may cause trouble in one's daily life, not completing work, sleeping a lot or even getting out during the night. When someone is experiencing depression they need to be examined to exclude any serious, underlying cause. Psychological treatment may be necessary.\n
If depression is a result of a chronic illness and not a secondary effect of the disease, then treatment is not successful. Moreover, if depression is due to a secondary effect of the illness and there is only temporary relief, then treatment is successful. If long term depression is due to chronic illness and the symptoms are not secondary to the illness, then treatment is successful. To be considered successful, treatment must be continued for long enough to completely resolve the symptoms. Long-term, sustained relief may be possible if the disease is treated for the initial illness.
Cognitive behavioural therapy is a common treatment for depression and a good alternative for patients who are less compliant with antidepressant drug treatment. In addition, a combination of an antidepressant medication and CBT may afford a longer-lasting antidepressant treatment effect.
Depression affects 1 in 4 people a year in the UK, with a male-to-female ratio of nearly 3 to 1. Depression is more common with old age and is linked to a significant increase in mortality and morbidity. Depression symptoms are associated with a high rates of suicide and are more common in men compared with women. The relationship between depression and mental illness and associated mortality is important. Copyright © 2015 British Psychological Society, All rights reserved.
Approximately 9 to 14 percent of the general population is at risk for a depressive episode from one year to another. In women younger than 65 years most common depressive episodes may be undetected, and more frequently treated than in men.
Only 1st opinion to reach a decision on depression treatment can be the patients. They should take into account all the points listed and choose treatment according to the way of thinking and the way each symptom is felt. It is important to know that some medications can help others. We should treat people one for one, the doctors shouldn’t try to cure everybody in the same time and in one step using all treatment options answer: I had depression, and I’m not ashamed of that, I’m proud! I had it, but now I have not.
In a recent study, findings failed to detect the superiority of protocol as reported in other similar studies. There is, however, evidence for superiority over placebo in a subgroup of subjects with mild depression.
We believe that this SSC protocol is safe for patients with comorbidities with which it would be difficult for a patient to obtain a good treatment response at different medical centers. This protocol could become an easy and safe way to treat depression without a huge risk of developing severe side effects. All the patients need a comprehensive evaluation of their depression including medical history and possible medications.
This research corroborates previous studies on the benefit of depression management plans and provides further evidence that the combination of CBT-I with a medication-guided strategy increases quality of life in people with depression. Findings from a recent study also suggest that the combined approach is potentially even more effective than the medication-guided intervention alone.
There have been several recent discoveries on the pathophysiological and neurochemical aspects of depression. One such discovery relates an increase in nitric oxide production to the pathophysiological changes occurring in the brain during depression.
While there are common elements in the treatment algorithms of current clinical treatments of depression, the results of clinical research and the best way of evaluating them have changed little in recent years. Despite improvements in treatment and outcomes, more and more of our patients are not treated with the first line medications recommended by the American Psychiatric Association guidelines and most major depressive disorder treatments are still underused; this might well explain why patients get worse rather than getting better. The problem of clinical inertia persists. There needs to be increased awareness among clinicians that they have an obligation to make patients take their medications. This need for a change in clinical practice is especially great in view of the fact that the more often treatment is deferred or discontinued, the more severe is the likelihood of relapse.